LY3938577 Phase 2 in type 2 diabetes (not a T1D result)
What this study tests
A Phase 2 comparison of LY3938577 with insulin degludec in adults with type 2 diabetes previously using basal insulin. Its primary aim is noninferiority on time in range. It is included as development context, not evidence of benefit in T1D.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-13.
Most recent recorded citation date: 2025-10-13. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-70 with type 2 diabetes previously treated with basal insulin. No type 1 diabetes participants. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- None posted. Started 13 October 2025, active and no longer recruiting as of August 2026, estimated enrolment 100, estimated completion December 2026. Sites in the United States and Argentina.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States, Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Change from baseline in glucose time in range 70-180 mg/dL inclusive (non-inferiority versus insulin degludec)
The full picture
Population and endpoint
This trial is entirely in type 2 diabetes. It compares LY3938577 with insulin degludec using change from baseline in time in 70–180 mg/dL through week 20 as its primary outcome, with a noninferiority design. The current registry record lists active, not recruiting and has no posted results.
Even a successful noninferiority result would need its confidence interval and prespecified margin to be interpreted. It would not by itself establish a glucose-responsive mechanism, prevention of hypoglycemia, or effectiveness in type 1 diabetes. Those are separate claims requiring relevant evidence.
Sources
- [1]A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin · Trial registry · 2025-10-13 — Phase 2, n=100 (estimated), started 13 Oct 2025, active not recruiting as of Aug 2026. Type 2 diabetes only. Primary endpoint is time in range 70-180 mg/dL, non-inferiority versus degludec. No results posted.